The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

Ainsworth Game Technology (ASX:AGI) jumped 32.4% since Thursday 24 April, finishing the week at 98 cents after announcing it ...

Good Afternoon and welcome to HotCopper Highlights for the end of Week 18, 2025, I’m Jonathon Davidson. In this segment we ...

These shares are having a good finish to the week. Let's find out why. The post Why Boss Energy, Capstone, Dimerix, and ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

The rare disease-focused biotech company posted adjusted earnings per share of $0.03, surpassing the analyst consensus estimate of -$0.02. However, revenue of $125.25 million missed Wall Street’s ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2). The ACTION3 trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients ...